Cargando…
The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals
Fifty years ago several thousand children were born with severe limb defects after their mothers had been given thalidomide in pregnancy. This tragedy caused procedures for licensing new medicines to become much stricter. Where, nevertheless, significant side effects were found it became common to s...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516063/ https://www.ncbi.nlm.nih.gov/pubmed/22908318 http://dx.doi.org/10.1093/qjmed/hcs148 |
_version_ | 1782252272289316864 |
---|---|
author | Lachmann, P.J. |
author_facet | Lachmann, P.J. |
author_sort | Lachmann, P.J. |
collection | PubMed |
description | Fifty years ago several thousand children were born with severe limb defects after their mothers had been given thalidomide in pregnancy. This tragedy caused procedures for licensing new medicines to become much stricter. Where, nevertheless, significant side effects were found it became common to sue for damages. These consequences have caused possibly an even greater disaster damaging many more people and threatening ruin to health services everywhere. The huge increase in both time and cost in bringing medicines to market is increasing their price to unsupportable levels; and only wealthy companies are now able to do so. This requires reform as does litigation for ‘statistical’ harmful effects. |
format | Online Article Text |
id | pubmed-3516063 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-35160632012-12-06 The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals Lachmann, P.J. QJM Original Papers Fifty years ago several thousand children were born with severe limb defects after their mothers had been given thalidomide in pregnancy. This tragedy caused procedures for licensing new medicines to become much stricter. Where, nevertheless, significant side effects were found it became common to sue for damages. These consequences have caused possibly an even greater disaster damaging many more people and threatening ruin to health services everywhere. The huge increase in both time and cost in bringing medicines to market is increasing their price to unsupportable levels; and only wealthy companies are now able to do so. This requires reform as does litigation for ‘statistical’ harmful effects. Oxford University Press 2012-12 2012-08-19 /pmc/articles/PMC3516063/ /pubmed/22908318 http://dx.doi.org/10.1093/qjmed/hcs148 Text en © The Author 2012. Published by Oxford University Press on behalf of the Association of Physicians. http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com. |
spellingShingle | Original Papers Lachmann, P.J. The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals |
title | The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals |
title_full | The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals |
title_fullStr | The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals |
title_full_unstemmed | The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals |
title_short | The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals |
title_sort | penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals |
topic | Original Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516063/ https://www.ncbi.nlm.nih.gov/pubmed/22908318 http://dx.doi.org/10.1093/qjmed/hcs148 |
work_keys_str_mv | AT lachmannpj thepenumbraofthalidomidethelitigationcultureandthelicensingofpharmaceuticals AT lachmannpj penumbraofthalidomidethelitigationcultureandthelicensingofpharmaceuticals |